Allogeneic Cell Therapy Devices Market By Device Type (Cell Culture Systems, Bioreactors, Cell Separation Systems, Cryopreservation Equipment, Cell Expansion Systems), By Application (Oncology, Cardiovascular Disorders, Neurological Disorders, Musculoskeletal Disorders, Autoimmune Diseases), By End-User (Academic & Research Institutes, Biopharmaceutical & Biotechnology Companies, Hospitals & Clinics, Contract Manufacturing Organizations), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Allogeneic Cell Therapy Devices Market was valued at USD 0.5 billion in 2023 and will surpass USD 1.9 billion by 2030; growing at a CAGR of 22.3% during 2024 - 2030.

The allogeneic cell therapy devices market is experiencing significant growth, driven by advancements in regenerative medicine and a rising prevalence of chronic diseases. Allogeneic therapies, which involve using donor cells to treat multiple patients, have spurred the demand for scalable and efficient manufacturing solutions. Key innovations in bioprocessing technologies have further catalyzed the adoption of these devices, making them an integral part of cell therapy production workflows.

Cell Expansion Systems Segment is Largest Owing to Increasing Demand for Scalable Manufacturing

Cell expansion systems represent the largest segment in the allogeneic cell therapy devices market, primarily due to their indispensable role in producing large volumes of cells required for therapies. These systems enable efficient growth and scaling of cells under controlled conditions, meeting the rigorous demands of commercial-scale production.

With the proliferation of biopharmaceutical companies and increasing investments in regenerative medicine, cell expansion systems have become central to the development pipeline. Their integration with automation technologies has further enhanced their efficiency, enabling faster and more reliable cell expansion processes for allogeneic applications.

Oncology Application is Fastest Growing Owing to Rising Cancer Prevalence

The oncology segment is the fastest-growing application area, attributed to the increasing prevalence of cancer worldwide and the growing adoption of allogeneic cell therapies in oncology. These therapies, including CAR-T cell treatments, offer transformative potential in addressing various hematological malignancies and solid tumors.

Biopharmaceutical companies are heavily investing in developing novel cell-based oncology treatments, driving the demand for specialized devices. Regulatory approvals and clinical successes in this space are also bolstering growth, as the oncology field remains at the forefront of cell therapy advancements.

Biopharmaceutical & Biotechnology Companies Segment is Largest Owing to High Utilization in Manufacturing

Biopharmaceutical and biotechnology companies account for the largest share in the end-user segment, as they are the primary entities driving cell therapy research, development, and commercialization. These organizations require advanced devices for large-scale cell manufacturing, including expansion, separation, and preservation technologies.

The rapid pace of R&D activities, coupled with robust funding and collaborations, has positioned biopharmaceutical companies as key contributors to market growth. Their reliance on high-throughput and automated systems underscores the demand for sophisticated allogeneic cell therapy devices.

Cryopreservation Equipment Segment is Fastest Growing Owing to Increasing Need for Cell Viability

Cryopreservation equipment is the fastest-growing segment within device types, driven by the critical need to maintain cell viability during storage and transportation. Allogeneic therapies often require long-distance transportation of donor cells, necessitating advanced cryopreservation solutions to ensure their integrity and functionality.

Recent innovations in cryopreservation technology, including the development of cryobags and vitrification techniques, have enhanced the reliability of this equipment. With global cell therapy distribution on the rise, the demand for robust cryopreservation systems continues to escalate.

North America is the Largest Region Owing to Strong R&D Infrastructure

North America holds the largest share of the allogeneic cell therapy devices market, supported by a well-established biotechnology and pharmaceutical industry. The region’s robust R&D infrastructure, favorable regulatory environment, and strong funding for regenerative medicine are key drivers of growth.

The United States, in particular, leads in terms of clinical trials and product approvals, providing a fertile ground for market expansion. Collaborations between academic institutions and industry players further reinforce North America's dominance in the sector.

Competitive Landscape

The allogeneic cell therapy devices market is highly competitive, with key players focusing on technological innovations and strategic partnerships to gain a competitive edge. Companies like Thermo Fisher Scientific, Lonza Group, and Sartorius AG are investing heavily in R&D to enhance their product offerings. Mergers, acquisitions, and collaborations are common strategies, aimed at expanding market presence and driving innovation.

As competition intensifies, differentiation through advanced features, scalability, and cost-effectiveness remains critical for sustained market leadership. The increasing involvement of startups and emerging players adds to the dynamic nature of the competitive landscape.

Recent Developments:

• Thermo Fisher Scientific announced the launch of a new automated cell therapy manufacturing platform aimed at enhancing scalability and efficiency in allogeneic therapies.
• Lonza Group partnered with a biotech firm to develop next-generation allogeneic cell therapy solutions targeting autoimmune disorders.
• Sartorius AG acquired a cell culture media company to expand its cell therapy portfolio, enhancing its offerings in allogeneic therapies.
• Corning Incorporated launched advanced bioreactor systems specifically designed for large-scale allogeneic therapy manufacturing.
• Cytiva (Danaher Corporation) received regulatory approval for a bioprocessing platform designed to streamline allogeneic cell therapy production

List of Leading Companies:

• Thermo Fisher Scientific
• Lonza Group
• Merck KGaA
• Sartorius AG
• Corning Incorporated
• Cytiva (Danaher Corporation)
• Terumo Corporation
• Eppendorf AG
• Bio-Techne Corporation
• Miltenyi Biotec
• STEMCELL Technologies
• Fujifilm Irvine Scientific
• CellGenix GmbH
• Beckman Coulter (Danaher Corporation)
• Bluebird Bio, Inc.

Report Scope: